Dec 19 (Reuters) - BioMarin Pharmaceutical (BMRN) said on Friday it would acquire Amicus Therapeutics (FOLD) for about $4.8 billion, expanding its presence in rare metabolic diseases.
The drugmaker will pay $14.50 per share for Amicus, a premium of 33.1% to the stock's last close. Shares of Amicus surged 30%, while BioMarin rose nearly 5% in premarket trading.
The deal strengthens BioMarin's portfolio with Amicus' approved genetic disorder treatments including Galafold, an oral drug for Fabry disease, which is caused by a faulty gene that leads to a buildup of fatty substances in cells.
Amicus also markets a combination therapy Pombiliti and Opfolda for Pompe disease, a genetic condition in which a complex sugar called glycogen builds up in the body's cells.
Amicus also has U.S. rights to DMX-200, a potential treatment of a type of kidney disease known as focal segmental glomerulosclerosis.
BioMarin intends to finance the deal through a combination of cash on hand and about $3.7 billion of non-convertible debt financing.
The company's total cash and investments at the end of September 30 were about $2 billion.
The acquisition, which is expected to close in the second quarter of 2026, will add revenue immediately after the transaction closes, BioMarin said.
The deal is also expected to add to adjusted profit in the first 12 months after close and be substantially accretive beginning in 2027, the company said.
(Reporting by Christy Santhosh and Sriparna Roy in Bengaluru; Editing by Leroy Leo and Maju Samuel)
LATEST POSTS
- 1
Palestinians reel under winter rains as Israel blocks Gaza shelter supplies - 2Mexico says a third of 130,000 missing people might be alive, fueling criticism from families
- 3White House responds to Sabrina Carpenter after pop star slams 'evil' ICE video using her song
- 4Incredible Travel Objections for Craftsmanship Darlings to Visit
- 5UK to hold fresh pork, other affected Spanish products at border amid African swine fever outbreak
- From record warming to rusting rivers, 2025 Arctic Report Card shows a region transforming faster than expected
- The Force of Systems administration: Individual Examples of overcoming adversity
- Saucony's $125 'Comfy, Stylish' Sneakers Are Now $55
- A definitive Handbook for Securities exchange Money management
- First part of major new German-Danish tunnel cleared for lowering
- How to sound like an astronaut as you follow the first human moon mission in more than half a century
- Eli Lilly to build $6 billion Alabama plant as part of US manufacturing push
- South Carolina confirms 124 new measles cases as outbreak on the Arizona-Utah line grows
- Is new Harry Styles music on the way? Fans think so, after a cryptic website and posters pop up.
